{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:27:16Z","timestamp":1791318436637,"version":"4.3.1"},"reference-count":200,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Unfractionated heparin has multiple pharmacological activities beyond anticoagulation. These anti-inflammatory, anti-microbial, and mucoactive activities are shared in part by low molecular weight and non-anticoagulant heparin derivatives. Anti-inflammatory activities include inhibition of chemokine activity and cytokine synthesis, inhibitory effects on the mechanisms of adhesion and diapedesis involved in neutrophil recruitment, inhibition of heparanase activity, inhibition of the proteases of the coagulation and complement cascades, inhibition of neutrophil elastase activity, neutralisation of toxic basic histones, and inhibition of HMGB1 activity. This review considers the potential for heparin and its derivatives to treat inflammatory lung disease, including COVID-19, ALI, ARDS, cystic fibrosis, asthma, and COPD via the inhaled route.<\/jats:p>","DOI":"10.3390\/ph16040584","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T02:03:38Z","timestamp":1681437818000},"page":"584","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease"],"prefix":"10.3390","volume":"16","author":[{"given":"Janis Kay","family":"Shute","sequence":"first","affiliation":[{"name":"School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth PO1 2UP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10719-016-9749-0","article-title":"Mast cell glycosaminoglycans","volume":"34","author":"Mulloy","year":"2017","journal-title":"Glycoconj. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3389\/fmed.2018.00360","article-title":"Bovine Mucosal Heparins Are Comparable to Porcine Mucosal Heparin at USP Potency Adjusted Levels","volume":"5","author":"Jeske","year":"2019","journal-title":"Front. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/1076029616643822","article-title":"Analysis of Heparins Derived from Bovine Tissues and Comparison to Porcine Intestinal Heparins","volume":"22","author":"Ange","year":"2016","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/pr.115.011247","article-title":"Pharmacology of Heparin and Related Drugs","volume":"68","author":"Mulloy","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-3-642-23056-1_3","article-title":"The Anticoagulant and Antithrombotic Mechanisms of Heparin","volume":"Volume 207","author":"Gray","year":"2012","journal-title":"Heparin\u2014A Century of Progress"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","article-title":"Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/j.1538-7836.2009.03461.x","article-title":"Biosimilar low molecular weight heparin products","volume":"7","author":"Gray","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"ref_8","first-page":"95","article-title":"Pharmacological and clinical differences between low-molecular-weight heparins: Implications for prescribing practice and therapeutic interchange","volume":"35","author":"Merli","year":"2010","journal-title":"Pharm. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1021\/acs.jmedchem.0c02019","article-title":"Preparation of Low Molecular Weight Heparin from a Remodeled Bovine Intestinal Heparin","volume":"64","author":"Baytas","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1161\/ATVBAHA.120.315728","article-title":"Major Reservoir for Heparin-Releasable TFPI\u03b1 (Tissue Factor Pathway Inhibitor \u03b1) Is Extracellular Matrix","volume":"41","author":"Peterson","year":"2021","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_11","first-page":"96","article-title":"Heparins-anionic polyelectrolyte drugs","volume":"31","author":"Jaques","year":"1979","journal-title":"Pharmacol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","article-title":"Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin","volume":"332","author":"Warkentin","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/pgmj.2007.059188","article-title":"Heparin induced thrombocytopenia: Diagnosis and management update","volume":"83","author":"Ahmed","year":"2007","journal-title":"Postgrad. Med. J."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mohamed, S., and Coombe, D.R. (2017). Heparin Mimetics: Their Therapeutic Potential. Pharmaceuticals, 10.","DOI":"10.3390\/ph10040078"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1021\/acs.bioconjchem.2c00316","article-title":"When Will Fondaparinux Induce Thrombocytopenia?","volume":"33","author":"Chen","year":"2022","journal-title":"Bioconjug. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"19892","DOI":"10.1074\/jbc.M111.228114","article-title":"A Systems Biology Approach for the Investigation of the Heparin\/Heparan Sulfate Interactome","volume":"286","author":"Ori","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.sbi.2015.05.007","article-title":"Current structural biology of the heparin interactome","volume":"34","author":"Pomin","year":"2015","journal-title":"Curr. Opin. Struct. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1182\/blood-2010-06-292938","article-title":"Heparin modifies the immunogenicity of positively charged proteins","volume":"116","author":"Chudasama","year":"2010","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00216-010-4220-8","article-title":"Protamine neutralisation of low molecular weight heparins and their oligosaccharide components","volume":"399","author":"Schroeder","year":"2011","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1742-1241.2002.tb11334.x","article-title":"Fondaparinux (Arixtra): A new anticoagulant","volume":"56","author":"Giangrande","year":"2002","journal-title":"Int. J. Clin. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/0049-3848(77)90117-7","article-title":"Primary structure of human platelet factor 4","volume":"11","author":"Walz","year":"1977","journal-title":"Thromb. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1161\/ATVBAHA.118.311102","article-title":"Glycosaminoglycan Neutralization in Coagulation Control","volume":"38","author":"Sobczak","year":"2018","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12185-014-1702-z","article-title":"Effects of factor VIII levels on the APTT and anti-Xa activity under a therapeutic dose of heparin","volume":"101","author":"Mitsuguro","year":"2015","journal-title":"Int. J. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pupt.2017.10.001","article-title":"Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: A pilot study","volume":"48","author":"Shute","year":"2018","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1160\/th15-03-0214","article-title":"Neutralisation of the anti-coagulant effects of heparin by histones in blood plasma and purified systems","volume":"115","author":"Hogwood","year":"2016","journal-title":"Thromb. Haemost."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1055\/s-0038-1648515","article-title":"Heparin binding to plasma proteins, an important mechanism for heparin resistance","volume":"67","author":"Young","year":"1992","journal-title":"Thromb. Haemost."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/33340","article-title":"Chemokines and leukocyte traffic","volume":"392","author":"Baggiolini","year":"1998","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"12959","DOI":"10.1021\/bi990711d","article-title":"Glycosaminoglycans Interact Selectively with Chemokines and Modulate Receptor Binding and Cellular Responses","volume":"38","author":"Kuschert","year":"1999","journal-title":"Biochemistry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1073\/pnas.0334864100","article-title":"Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines","volume":"100","author":"Proudfoot","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/03008200802148595","article-title":"The Activities of Heparan Sulfate and its Analogue Heparin are Dictated by Biosynthesis, Sequence, and Conformation","volume":"49","author":"Skidmore","year":"2008","journal-title":"Connect. Tissue Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.carbpol.2014.09.079","article-title":"Heparin derivatives for the targeting of multiple activities in the inflammatory response","volume":"117","author":"Veraldi","year":"2015","journal-title":"Carbohydr. Polym."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1172\/JCI1509","article-title":"Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents","volume":"101","author":"Koenig","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/sj.bjp.0707298","article-title":"Size-fractionated heparins have differential effects on human neutrophil function in vitro","volume":"151","author":"Lever","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejphar.2009.12.015","article-title":"Locally available heparin modulates inflammatory cell recruitment in a manner independent of anticoagulant activity","volume":"630","author":"Lever","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1083\/jcb.130.6.1473","article-title":"Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b\/CD1)","volume":"130","author":"Diamond","year":"1995","journal-title":"J. Cell. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/gut.47.1.88","article-title":"Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism","volume":"47","author":"Salas","year":"2000","journal-title":"Gut"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"9104","DOI":"10.1021\/bi060338r","article-title":"New Insights into the Inhibition of Human Neutrophil Elastase by Heparin","volume":"45","author":"Spencer","year":"2006","journal-title":"Biochemistry"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"C97","DOI":"10.1152\/ajpcell.00009.2010","article-title":"Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands","volume":"299","author":"Rao","year":"2010","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1046\/j.1538-7836.2003.00305.x","article-title":"Mechanisms of glycosaminoglycan activation of the serpins in hemostasis","volume":"1","author":"Huntington","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.biochi.2008.01.004","article-title":"Alpha-1-proteinase inhibitor is a heparin binding serpin: Molecular interactions with the Lys rich cluster of helix-F domain","volume":"90","author":"Gupta","year":"2008","journal-title":"Biochimie"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"13563","DOI":"10.1074\/jbc.273.22.13563","article-title":"Interaction of Secretory Leukocyte Protease Inhibitor with Heparin Inhibits Proteases Involved in Asthma","volume":"273","author":"Fath","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2119\/molmed.2013.00164","article-title":"The Role of HMGB1 in the Pathogenesis of Inflammatory and Autoimmune Diseases","volume":"20","author":"Magna","year":"2014","journal-title":"Mol. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s10787-022-00988-y","article-title":"High-mobility group box 1 (HMGB1) in COVID-19: Extrapolation of dangerous liaisons","volume":"30","author":"Alkazmi","year":"2022","journal-title":"Inflammopharmacology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cyto.2014.12.010","article-title":"Heparin inhibits the inflammatory response induced by LPS and HMGB1 by blocking the binding of HMGB1 to the surface of macrophages","volume":"72","author":"Li","year":"2015","journal-title":"Cytokine"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1165\/rcmb.2013-0338RC","article-title":"2-O, 3-O-Desulfated Heparin Inhibits Neutrophil Elastase\u2013Induced HMGB-1 Secretion and Airway Inflammation","volume":"50","author":"Griffin","year":"2014","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"C1184","DOI":"10.1152\/ajpcell.00269.2013","article-title":"Heparanase induces inflammatory cell recruitment in vivo by promoting adhesion to vascular endothelium","volume":"306","author":"Lever","year":"2014","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.2174\/138161207781039742","article-title":"Heparanase: Structure, Biological Functions, and Inhibition by Heparin-Derived Mimetics of Heparan Sulfate","volume":"13","author":"Vlodavsky","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/978-3-030-34521-1_20","article-title":"Non-Anticoagulant Heparins as Heparanase Inhibitors","volume":"1221","author":"Cassinelli","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"12103","DOI":"10.1074\/jbc.M414217200","article-title":"Modulation of the Heparanase-inhibiting Activity of Heparin through Selective Desulfation, Graded N-Acetylation, and Glycol Splitting","volume":"280","author":"Naggi","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1165\/rcmb.2013-0485TR","article-title":"Complement System in Lung Disease","volume":"51","author":"Pandya","year":"2014","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0162-3109(94)90049-3","article-title":"Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum","volume":"27","author":"Edens","year":"1994","journal-title":"Immunopharmacology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0162-3109(89)90051-9","article-title":"Comparison of the activity of polyanions and polycations on the classical and alternative pathways of complement","volume":"17","author":"Weiler","year":"1989","journal-title":"Immunopharmacology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"13090","DOI":"10.1016\/S0021-9258(18)37675-0","article-title":"Homogeneous, structurally defined heparin-oligosaccharides with low anticoagulant activity inhibit the generation of the amplification pathway C3 convertase in vitro","volume":"263","author":"Linhardt","year":"1988","journal-title":"J. Biol. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.4049\/jimmunol.148.10.3210","article-title":"Heparin and modified heparin inhibit complement activation in vivo","volume":"148","author":"Weiler","year":"1992","journal-title":"J. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1378\/chest.129.5.1148","article-title":"Pulmonary Function Is Negatively Correlated with Sputum Inflammatory Markers and Cough Clearability in Subjects with Cystic Fibrosis But Not Those with Chronic Bronchitis","volume":"129","author":"Kim","year":"2006","journal-title":"Chest"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"L1240","DOI":"10.1152\/ajplung.00206.2007","article-title":"Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis","volume":"293","author":"Shur","year":"2007","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3389\/fimmu.2016.00311","article-title":"Neutrophil extracellular traps in pulmonary diseases: Too much of a good thing?","volume":"7","author":"Porto","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1093\/humrep\/deg354","article-title":"Heparan sulphate: A putative decondensing agent for human spermatozoa in vivo","volume":"18","author":"Romanato","year":"2003","journal-title":"Hum. Reprod."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"15880","DOI":"10.1073\/pnas.1005743107","article-title":"Extracellular DNA traps promote thrombosis","volume":"107","author":"Fuchs","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.phrs.2016.08.008","article-title":"Low molecular weight heparins prevent the induction of autophagy of activated neutrophils and the formation of neutrophil extracellular traps","volume":"123","author":"Manfredi","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/intimm\/dxz084","article-title":"Heparin induces neutrophil elastase-dependent vital and lytic NET formation","volume":"32","author":"Lelliott","year":"2020","journal-title":"Int. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jaci.2003.12.034","article-title":"Acid stress in the pathology of asthma","volume":"113","author":"Ricciardolo","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1172\/JCI83922","article-title":"Acidic pH increases airway surface liquid viscosity in cystic fibrosis","volume":"126","author":"Tang","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000195961","article-title":"Role of Enzymes from Inflammatory Cells on Airway Submucosal Gland Secretion","volume":"58","author":"Nadel","year":"1991","journal-title":"Respiration"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1097\/CCM.0000000000004458","article-title":"Coagulopathy of Coronavirus Disease 2019","volume":"48","author":"Iba","year":"2020","journal-title":"Crit. Care Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e12113","DOI":"10.1002\/pul2.12113","article-title":"The PVRI Innovative Drug Development Initiative Pulmonary thromboembolic events in COVID-19\u2014A systematic literature review","volume":"12","author":"Overton","year":"2022","journal-title":"Pulm. Circ."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2213-2600(20)30216-2","article-title":"COVID-19 cytokine storm: The interplay between inflammation and coagulation","volume":"8","author":"Jose","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jth.12047","article-title":"Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndrome","volume":"11","author":"Glas","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.jacc.2021.02.035","article-title":"Recent Randomized Trials of Antithrombotic Therapy for Patients with COVID-19. JACC state-of-the-art review","volume":"77","author":"Talasaz","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1111\/jth.15808","article-title":"ISTH guidelines for antithrombotic treatment in COVID-19","volume":"20","author":"Schulman","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1111\/jth.15464","article-title":"Heparin\u2013Messias or Verschlimmbesserung?","volume":"19","author":"Swan","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"10760296221131802","DOI":"10.1177\/10760296221131802","article-title":"In-hospital Mortality Rates in SARS-CoV-2 Patients Treated with Enoxaparin and Heparin","volume":"28","author":"Alroomi","year":"2022","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s11239-020-02162-z","article-title":"The association between treatment with heparin and survival in patients with COVID-19","volume":"50","author":"Ayerbe","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fphar.2020.01124","article-title":"Preliminary Experience with Low Molecular Weight Heparin Strategy in COVID-19 Patients","volume":"11","author":"Paolisso","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacc.2020.05.001","article-title":"Association of Treatment Dose Anticoagulation with In-Hospital Survival among Hospitalized Patients with COVID-19","volume":"76","author":"Paranjpe","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11239-020-02145-0","article-title":"Heparin resistance in COVID-19 patients in the intensive care unit","volume":"50","author":"White","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2020.05.049","article-title":"Image-proven thromboembolism in patients with severe COVID-19 in a tertiary critical care unit in the United Kingdom","volume":"193","author":"Desborough","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/rth2.12390","article-title":"Heparin-induced thrombocytopenia with thrombosis in COVID-19 adult respiratory distress syndrome","volume":"4","author":"Riker","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00428-022-03319-2","article-title":"Organ manifestations of COVID-19: What have we learned so far (not only) from autopsies?","volume":"481","author":"Jonigk","year":"2022","journal-title":"Virchows Arch."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/s13054-020-03148-2","article-title":"Nebulised heparin as a treatment for COVID-19: Scientific rationale and a call for randomised evidence","volume":"24","author":"Page","year":"2020","journal-title":"Crit. Care"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.7861\/clinmed.2020-0351","article-title":"Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19","volume":"20","author":"Conzelmann","year":"2020","journal-title":"Clin. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1111\/bcp.15212","article-title":"Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patients","volume":"88","author":"Steins","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-2600(20)30470-7","article-title":"Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: A multicentre, randomised, double-blind, placebo-controlled phase 3 trial","volume":"9","author":"Dixon","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e115938","DOI":"10.5812\/aapm.115938","article-title":"Effect of Nebulized Heparin on Weaning off Intubated Patients with Acute Respiratory Distress Syndrome (ARDS) Admitted to Intensive Care Unit (ICU): A Randomized Clinical Trial","volume":"11","author":"Olapour","year":"2021","journal-title":"Anesthesiol. Pain Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1111\/bcp.14714","article-title":"INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): Protocol and statistical analysis plan for an investigator-initiated international metatrial of randomised studies","volume":"87","author":"Richardson","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1111\/bcp.15253","article-title":"Can nebulised HepArin Reduce morTality and time to Extubation in patients with COVID-19 Requiring invasive ventilation Meta-Trial (CHARTER-MT): Protocol and statistical analysis plan for an investigator-initiated international meta-trial of prospective randomised clinical studies","volume":"88","author":"Laffey","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1186\/s13063-022-06518-z","article-title":"The CHARTER-Ireland trial: Can nebulised heparin reduce acute lung injury in patients with SARS-CoV-2 requiring advanced respiratory support in Ireland: A study protocol and statistical analysis plan for a randomised control trial","volume":"23","author":"Sheehan","year":"2022","journal-title":"Trials"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Erelel, M., Kaskal, M., Akbal-Dagistan, O., Issever, H., Dagistanli, A.S., Balkanci, H., Oguz, M.S., Qarayeva, A., Culha, M., and Erturk, A. (2021). Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13111768"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Cagno, V., Tseligka, E.D., Jones, S.T., and Tapparel, C. (2019). Heparan Sulfate Proteoglycans and Viral Attachment: True Receptors or Adaptation Bias?. Viruses, 11.","DOI":"10.3390\/v11070596"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","article-title":"SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2","volume":"183","author":"Clausen","year":"2020","journal-title":"Cell"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"101507","DOI":"10.1016\/j.jbc.2021.101507","article-title":"The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms","volume":"298","author":"Paiardi","year":"2022","journal-title":"J. Biol. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/bph.15304","article-title":"Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations","volume":"178","author":"Tree","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/978-3-030-34521-1_21","article-title":"Roneparstat: Development, Preclinical and Clinical Studies","volume":"1221","author":"Noseda","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/978-3-030-34521-1_32","article-title":"Heparanase, Heparan Sulfate and Viral Infection","volume":"1221","author":"Agelidis","year":"2020","journal-title":"Heparanase"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e0005722","DOI":"10.1128\/jvi.00057-22","article-title":"Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19","volume":"96","author":"Xiang","year":"2022","journal-title":"J. Virol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e28124","DOI":"10.1002\/jmv.28124","article-title":"Native and activated antithrombin inhibits TMPRSS2 activity and SARS-CoV-2 infection","volume":"95","author":"Wettstein","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_98","first-page":"255","article-title":"Bronchoalveolar lavage and plasma Antithrombin and cytokines in inhalation and burn injury: A pilot study","volume":"10","author":"Dennis","year":"2020","journal-title":"Int. J. Burns Trauma"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1126\/science.abc3517","article-title":"Estimating the burden of SARS-CoV-2 in France","volume":"369","author":"Salje","year":"2020","journal-title":"Science"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/jmv.25822","article-title":"Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: A systematic review and meta-analysis","volume":"92","author":"Cao","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.csbj.2021.01.034","article-title":"Chemokines and chemokine receptors during COVID-19 infection","volume":"19","author":"Khalil","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"9502","DOI":"10.1038\/s41598-022-13179-0","article-title":"Identification of bronchoalveolar and blood immune-inflammatory biomarker signature associated with poor 28-day outcome in critically ill COVID-19 patients","volume":"12","author":"Voiriot","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.immuni.2021.03.005","article-title":"Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19","volume":"54","author":"Szabo","year":"2021","journal-title":"Immunity"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1084\/jem.177.6.1821","article-title":"Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes","volume":"177","author":"Schall","year":"1993","journal-title":"J. Exp. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jaci.2021.05.032","article-title":"Chemokines and eicosanoids fuel the hyperinflammation within the lungs of patients with severe COVID-19","volume":"148","author":"Zaid","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.jaci.2021.03.047","article-title":"Distinct cytokine profiles associated with COVID-19 severity and mortality","volume":"147","author":"Dorgham","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/BOR.0000000000000822","article-title":"Is severe COVID-19 a cytokine storm syndrome: A hyperinflammatory debate","volume":"33","author":"Mehta","year":"2021","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"eabg9873","DOI":"10.1126\/sciimmunol.abg9873","article-title":"Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19","volume":"6","author":"Thwaites","year":"2021","journal-title":"Sci. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","article-title":"Longitudinal analyses reveal immunological misfiring in severe COVID-19","volume":"584","author":"Lucas","year":"2020","journal-title":"Nature"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Pandolfi, L., Fossali, T., Frangipane, V., Bozzini, S., Morosini, M., D\u2019Amato, M., Lettieri, S., Urtis, M., Di Toro, A., and Saracino, L. (2020). Broncho-alveolar inflammation in COVID-19 patients: A correlation with clinical outcome. BMC Pulm. Med., 20.","DOI":"10.1186\/s12890-020-01343-z"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"808797","DOI":"10.3389\/fphar.2021.808797","article-title":"The Role of Interleukin-8 in Lung Inflammation and Injury: Implications for the Management of COVID-19 and Hyperinflammatory Acute Respiratory Distress Syndrome","volume":"12","author":"Cesta","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"117232","DOI":"10.1016\/j.carbpol.2020.117232","article-title":"Comprehensive Landscape of Heparin Therapy for COVID-19","volume":"254","author":"Shi","year":"2021","journal-title":"Carbohydr. Polym."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/cts.12880","article-title":"The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID-19 Patients: A Retrospective Cohort Study","volume":"13","author":"Shi","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"575047","DOI":"10.3389\/fimmu.2020.575047","article-title":"Increased Plasma Heparanase Activity in COVID-19 Patients","volume":"11","author":"Buijsers","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.4049\/jimmunol.165.10.5671","article-title":"Characterization of the Heparin-Binding Properties of IL-6","volume":"165","author":"Mummery","year":"2000","journal-title":"J. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2217\/imt-2016-0020","article-title":"Immunotherapeutic implications of IL-6 blockade for cytokine storm","volume":"8","author":"Tanaka","year":"2016","journal-title":"Immunotherapy"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"22351","DOI":"10.1073\/pnas.2010229117","article-title":"IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome","volume":"117","author":"Kang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Sardu, C., Gambardella, J., Morelli, M.B., Wang, X., Marfella, R., and Santulli, G. (2020). Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. J. Clin. Med., 9.","DOI":"10.20944\/preprints202004.0204.v1"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"119376","DOI":"10.1016\/j.lfs.2021.119376","article-title":"Heparin prevents in vitro glycocalyx shedding induced by plasma from COVID-19 patients","volume":"276","author":"Potje","year":"2021","journal-title":"Life Sci."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1182\/blood-2018-11-844530","article-title":"Neutrophils and NETs in modulating acute and chronic inflammation","volume":"133","author":"Castanheira","year":"2019","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1038\/s41418-021-00805-z","article-title":"Patients with COVID-19: In the dark-NETs of neutrophils","volume":"28","author":"Ackermann","year":"2021","journal-title":"Cell. Death Differ."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s11239-020-02324-z","article-title":"Neutrophil extracellular traps and thrombosis in COVID-19","volume":"51","author":"Zuo","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e20200652","DOI":"10.1084\/jem.20200652","article-title":"Targeting potential drivers of COVID-19: Neutrophil extracellular traps","volume":"217","author":"Barnes","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_124","first-page":"e138999","article-title":"Neutrophil extracellular traps in COVID-19","volume":"5","author":"Zuo","year":"2020","journal-title":"JCI Insight"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e2250010","DOI":"10.1002\/eji.202250010","article-title":"Neutrophil activation and neutrophil extracellular traps (NETs) in COVID-19 ARDS and immunothrombosis","volume":"53","author":"Cesta","year":"2023","journal-title":"Eur. J. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.chest.2022.06.007","article-title":"Neutrophil Extracellular Traps, Local IL-8 Expression, and Cytotoxic T-Lymphocyte Response in the Lungs of Patients with Fatal COVID-19","volume":"162","author":"Melero","year":"2022","journal-title":"Chest"},{"key":"ref_127","first-page":"275","article-title":"The role of extracellular histones in COVID-19","volume":"293","author":"Huckriede","year":"2022","journal-title":"J. Intern. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.molimm.2021.04.002","article-title":"Extracellular histones aggravate inflammation in ARDS by promoting alveolar macrophage pyroptosis","volume":"135","author":"Jiang","year":"2021","journal-title":"Mol. Immunol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood-2013-07-514984","article-title":"Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis","volume":"123","author":"Wildhagen","year":"2014","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Hogwood, J., Pitchford, S., Mulloy, B., Page, C., and Gray, E. (2020). Heparin and non-anticoagulant heparin attenuate histone-induced inflammatory responses in whole blood. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0233644"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12979-022-00315-7","article-title":"Biomarkers of cell damage, neutrophil and macrophage activation associated with in-hospital mortality in geriatric COVID-19 patients","volume":"19","author":"Cardelli","year":"2022","journal-title":"Immun. Ageing"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"103894","DOI":"10.1016\/j.ebiom.2022.103894","article-title":"Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implications","volume":"77","author":"McElvaney","year":"2022","journal-title":"Ebiomedicine"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Ceccato, A., Camprub\u00ed-Rimblas, M., Campa\u00f1a-Duel, E., Areny-Balaguer\u00f3, A., Morales-Quinteros, L., and Artigas, A. (2022). Anticoagulant Treatment in Severe ARDS COVID-19 Patients. J. Clin. Med., 11.","DOI":"10.3390\/jcm11102695"},{"key":"ref_134","first-page":"961784","article-title":"Bronchoalveolar Activation of Coagulation and Inhibition of Fibrinolysis during Ventilator-Associated Lung Injury","volume":"2012","author":"Schultz","year":"2012","journal-title":"Crit. Care Res. Pract."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/cc6894","article-title":"A phase 1 trial of nebulised heparin in acute lung injury","volume":"12","author":"Dixon","year":"2008","journal-title":"Crit. Care"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1186\/cc9269","article-title":"Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury","volume":"14","author":"Dixon","year":"2010","journal-title":"Crit. Care"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"R180","DOI":"10.1186\/cc9286","article-title":"Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: A randomized controlled trial","volume":"14","author":"Dixon","year":"2010","journal-title":"Crit. Care"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13613-016-0138-4","article-title":"Nebulized heparin for patients under mechanical ventilation: An individual patient data meta-analysis","volume":"6","author":"Glas","year":"2016","journal-title":"Ann. Intensiv. Care"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jcrc.2016.06.022","article-title":"Is inhaled prophylactic heparin useful for prevention and management of pneumonia in ventilated ICU patients?","volume":"35","author":"Bandeshe","year":"2016","journal-title":"J. Crit. Care"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.resinv.2022.11.002","article-title":"Anti-inflammatory effects of medications used for viral infection-induced respiratory diseases","volume":"61","author":"Yamaya","year":"2023","journal-title":"Respir. Investig."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"865973","DOI":"10.3389\/fimmu.2022.865973","article-title":"Innate Immune Responses by Respiratory Viruses, Including Rhinovirus, During Asthma Exacerbation","volume":"13","author":"Nakagome","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Guo-Parke, H., Linden, D., Weldon, S., Kidney, J.C., and Taggart, C.C. (2022). Deciphering Respiratory-Virus-Associated Interferon Signaling in COPD Airway Epithelium. Medicina, 58.","DOI":"10.3390\/medicina58010121"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2147\/JEP.S255211","article-title":"Experimental Antiviral Therapeutic Studies for Human Rhinovirus Infections","volume":"13","author":"Coultas","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3389\/fimmu.2020.01327","article-title":"Rhinovirus Infection Drives Complex Host Airway Molecular Responses in Children with Cystic Fibrosis","volume":"11","author":"Ling","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.anai.2022.08.015","article-title":"T-helper 2 mechanisms involved in human rhinovirus infections and asthma","volume":"129","author":"Price","year":"2022","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_146","first-page":"871","article-title":"Impact of viral respiratory infections on pulmonary exacerbations in children with cystic fibrosis","volume":"58","author":"Kasi","year":"2022","journal-title":"Pediatr. Pulmonol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1034\/j.1399-3003.2000.16d19.x","article-title":"Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease","volume":"16","author":"Seemungal","year":"2000","journal-title":"Eur. Respir. J."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1128\/JVI.02160-06","article-title":"Human Rhinovirus Type 54 Infection via Heparan Sulfate Is Less Efficient and Strictly Dependent on Low Endosomal pH","volume":"81","author":"Khan","year":"2007","journal-title":"J. Virol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/nar\/28.1.27","article-title":"KEGG: Kyoto Encyclopedia of Genes and Genomes","volume":"28","author":"Kanehisa","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coph.2018.01.006","article-title":"Therapeutic use of heparin and derivatives beyond anticoagulation in patients with bronchial asthma or COPD","volume":"40","author":"Shute","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1517\/13543784.2014.866092","article-title":"Non-anticoagulant derivatives of heparin for the management of asthma: Distant dream or close reality?","volume":"23","author":"Shastri","year":"2013","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Kianian, F., Kadkhodaee, M., Sadeghipour, H.R., Karimian, S.M., and Seifi, B. (2020). An overview of high-mobility group box 1, a potent pro-inflammatory cytokine in asthma. J. Basic Clin. Physiol. Pharmacol., 31.","DOI":"10.1515\/jbcpp-2019-0363"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/thx.2009.114439","article-title":"Coagulation factors in the airways in moderate and severe asthma and the effect of inhaled steroids","volume":"64","author":"Brims","year":"2009","journal-title":"Thorax"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2011-11-391532","article-title":"Asthma and coagulation","volume":"119","author":"Majoor","year":"2012","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11882-017-0738-6","article-title":"Redefining Approaches to Asthma: Bridging the Gap Between Heparin and Its Anti-inflammatory Activities","volume":"17","author":"Shastri","year":"2017","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_156","first-page":"507151","article-title":"Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic Review","volume":"2015","author":"Mousavi","year":"2015","journal-title":"Adv. Pharmacol. Sci."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.thromres.2015.10.011","article-title":"Inhalational use of antithrombotics in humans: Review of the literature","volume":"136","author":"Monagle","year":"2015","journal-title":"Thromb. Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1164\/ajrccm.160.2.9812076","article-title":"Prevention of Exercise-induced Bronchoconstriction by Inhaled Low-molecular-weight Heparin","volume":"160","author":"Ahmed","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_159","first-page":"543","article-title":"Mechanizmy dzia\u0142ania heparyny ma\u0142oczasteczkowej nebulizowanej u chorych na astme oskrzelowa [Mechanisms of action of nebulized low molecular weights heparin in patients with bronchial asthma]","volume":"15","author":"Fal","year":"2003","journal-title":"Pol. Merkur. Lekarski."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1053\/rmed.1999.0677","article-title":"Inhaled heparin is effective in exacerbations of asthma","volume":"94","author":"Bendstrup","year":"2000","journal-title":"Respir. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"102037","DOI":"10.1016\/j.pupt.2021.102037","article-title":"Evaluation of efficacy of nebulized low molecular weight heparin as an adjunctive extra treatment for acute mild-moderate asthma attack; a randomized clinical trial study","volume":"68","author":"Motamed","year":"2021","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1002\/iid3.711","article-title":"The role of HMGB1\/RAGE\/TLR4 signaling pathways in cigarette smoke-induced inflammation in chronic obstructive pulmonary disease","volume":"10","author":"Lin","year":"2022","journal-title":"Immunity Inflamm. Dis."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/00325481.2022.2124087","article-title":"Role of RAGE and its ligand HMGB1 in the development of COPD","volume":"134","author":"Chen","year":"2022","journal-title":"Postgrad. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4097\/kja.19418","article-title":"Nebulized heparin and salbutamol versus salbutamol alone in acute exacerbations of chronic obstructive pulmonary disease requiring mechanical ventilation: A double-blind randomized controlled trial","volume":"73","author":"Ashoor","year":"2020","journal-title":"Korean J. Anesthesiol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1055\/s-0042-1758728","article-title":"Respiratory Viruses and Cystic Fibrosis","volume":"44","author":"Brackenborough","year":"2023","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1080\/1040841X.2017.1297763","article-title":"Viruses in cystic fibrosis patients\u2019 airways","volume":"43","author":"Billard","year":"2017","journal-title":"Crit. Rev. Microbiol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.3389\/fimmu.2018.03067","article-title":"Viral-Bacterial Co-infections in the Cystic Fibrosis Respiratory Tract","volume":"9","author":"Kiedrowski","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1203\/pdr.0b013e3180332d1c","article-title":"RSV Mediates Pseudomonas aeruginosa Binding to Cystic Fibrosis and Normal Epithelial Cells","volume":"61","author":"Wolfs","year":"2007","journal-title":"Pediatr. Res."},{"key":"ref_169","first-page":"157","article-title":"The antimicrobial effect of heparin on common respiratory pathogens","volume":"9","author":"Zappala","year":"2007","journal-title":"Crit. Care Resusc."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Lor\u00e8, N.I., Veraldi, N., Riva, C., Sipione, B., Spagnuolo, L., De Fino, I., Melessike, M., Calzi, E., Bragonzi, A., and Naggi, A. (2018). Synthesized Heparan Sulfate Competitors Attenuate Pseudomonas aeruginosa Lung Infection. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010207"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.jcf.2018.10.017","article-title":"Glycosaminoglycans are differentially involved in bacterial binding to healthy and cystic fibrosis lung cells","volume":"18","author":"Martin","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3109\/1547691X.2013.839587","article-title":"Partially-desulfated heparin improves survival in Pseudomonas pneumonia by enhancing bacterial clearance and ameliorating lung injury","volume":"11","author":"Sharma","year":"2014","journal-title":"J. Immunotoxicol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s10020-021-00334-y","article-title":"2-O, 3-O desulfated heparin (ODSH) increases bacterial clearance and attenuates lung injury in cystic fibrosis by restoring HMGB1-compromised macrophage function","volume":"27","author":"Wang","year":"2021","journal-title":"Mol. Med."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Harvey, C., Weldon, S., Elborn, S., Downey, D.G., and Taggart, C. (2022). The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073513"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00441-016-2562-z","article-title":"Airway mucus, inflammation and remodeling: Emerging links in the pathogenesis of chronic lung diseases","volume":"367","author":"Duerr","year":"2017","journal-title":"Cell. Tissue Res."},{"key":"ref_176","first-page":"S5","article-title":"Mucus obstruction and inflammation in early cystic fibrosis lung disease: Emerging role of the IL-1 signaling pathway","volume":"54","author":"Mall","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jcf.2015.03.003","article-title":"Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy","volume":"14","author":"Cantin","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jcf.2016.10.006","article-title":"Bacterial proteases and haemostasis dysregulation in the CF lung","volume":"16","author":"Reihill","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3389\/fphar.2020.01011","article-title":"Glycosaminoglycans as Multifunctional Anti-Elastase and Anti-Inflammatory Drugs in Cystic Fibrosis Lung Disease","volume":"11","author":"Voynow","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/febs.13932","article-title":"Heparanase regulation of cancer, autophagy and inflammation: New mechanisms and targets for therapy","volume":"284","author":"Sanderson","year":"2017","journal-title":"FEBS J."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jcf.2019.08.021","article-title":"Whole-blood transcriptomic responses to lumacaftor\/ivacaftor therapy in cystic fibrosis","volume":"19","author":"Kopp","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.carbpol.2016.09.032","article-title":"Structural features of heparanase-inhibiting non-anticoagulant heparin derivative Roneparstat","volume":"156","author":"Alekseeva","year":"2017","journal-title":"Carbohydr. Polym."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"408935","DOI":"10.1155\/2015\/408935","article-title":"Free DNA in Cystic Fibrosis Airway Fluids Correlates with Airflow Obstruction","volume":"2015","author":"Marcos","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1465-9921-10-63","article-title":"Macrorheology of cystic fibrosis, chronic obstructive pulmonary disease & normal sputum","volume":"10","author":"Serisier","year":"2009","journal-title":"Respir. Res."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S2213-2600(17)30311-9","article-title":"Clinical trial research in focus: Ensuring new cystic fibrosis drugs fulfil their potential","volume":"5","author":"Elborn","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_186","first-page":"A75","article-title":"Anti-inflammatory effects of nebulised heparin in cystic fibrosis [abstract]","volume":"161","author":"Shute","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1164\/ajrccm.160.5.9809123","article-title":"Lung Deposition and Clearance of Inhaled 99mTc-Heparin in Healthy Volunteers","volume":"160","author":"Bendstrup","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1183\/09031936.02.00105202","article-title":"Effect of inhaled heparin on lung function and coagulation in healthy volunteers","volume":"19","author":"Bendstrup","year":"2002","journal-title":"Eur. Respir. J."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1183\/09031936.01.17100360","article-title":"Nebulized heparin in Burkholderia cepacia colonized adult cystic fibrosis patients","volume":"17","author":"Ledson","year":"2001","journal-title":"Eur. Respir. J."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1183\/09031936.06.00069005","article-title":"Inhaled heparin in cystic fibrosis","volume":"27","author":"Serisier","year":"2006","journal-title":"Eur. Respir. J."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1513\/pats.200703-044BR","article-title":"Sputum Biomarkers of Inflammation in Cystic Fibrosis Lung Disease","volume":"4","author":"Sagel","year":"2007","journal-title":"Proc. Am. Thorac. Soc."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jpeds.2004.06.054","article-title":"Variability of markers of inflammation and infection in induced sputum in children with cystic fibrosis","volume":"145","author":"Kartashov","year":"2004","journal-title":"J. Pediatr."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1002\/jps.21362","article-title":"Cospray-dried unfractionated heparin with L-leucine as a dry powder inhaler mucolytic for cystic fibrosis therapy","volume":"97","author":"Shur","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/03639040701657552","article-title":"The Spray Drying of Unfractionated Heparin: Optimization of the Operating Parameters","volume":"34","author":"Shur","year":"2008","journal-title":"Drug. Dev. Ind. Pharm."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/jamp.2015.1273","article-title":"Inhaled Heparin: Therapeutic Efficacy and Recent Formulations","volume":"30","author":"Ozsoy","year":"2017","journal-title":"J. Aerosol Med. Pulm. Drug. Deliv."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2141.2005.05953.x","article-title":"The British Committee for Standards in Haematology Guidelines on the use and monitoring of heparin","volume":"133","author":"Baglin","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1055\/s-0037-1614170","article-title":"Characterization of unfractionated heparin: Comparison of materials from the last 50 years","volume":"84","author":"Mulloy","year":"2000","journal-title":"Thromb. Haemost."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(76)91679-2","article-title":"INTRAPULMONARY HEPARIN A New Procedure for Anticoagulant Therapy","volume":"308","author":"Jaques","year":"1976","journal-title":"Lancet"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/jamp.2009.0780","article-title":"Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis","volume":"23","author":"Markart","year":"2010","journal-title":"J. Aerosol Med. Pulm. Drug. Deliv."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"McCarthy, S.D., Gonz\u00e1lez, H.E., and Higgins, B.D. (2020). Future Trends in Nebulized Therapies for Pulmonary Disease. J. Pers. Med., 10.","DOI":"10.3390\/jpm10020037"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/4\/584\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:15:46Z","timestamp":1760123746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/4\/584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":200,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ph16040584"],"URL":"https:\/\/doi.org\/10.3390\/ph16040584","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]}}}